I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As I said many months ago, JAVACO is the biggest mistake that JB has made so far, IMHO. Nothing that cannot be overcome and turned into a positive someday but for now there are too many carts and we are still waiting for the first horse to show up. Where do you think that JBII's stock price would be right now without Javaco, media credits & Kidd shares (and probably no restatements)? I know hindsight is 20/20 but it is what is and to try and paint it differently shows a blind bias that discounts everything else that is stated.
I do not understand why it was not officially announced that the auditor change was mandated by the AGM vote when the change of auditor was announced? It would have given some confidence to the shareholders.
I do like the transition to professional communications and believe that the P2O process will be good enough to be profitable and have JV's lined up to take their offer making the current price ($.76) a nice opportunity for the next years worth of growth. In my mind it needs to have a decent profit margin to be successful for the long-term.
I'm concerned now...
It does look like a capitulation bottom today (IMHO) and I am not done buying as I have funds clearing next week. If the price takes off from here that would really stink - lol
Good to see volume at least and I don't fear any pipe shares hitting the market at $.75 or less.
The way I view it, JBI is in transition from over-promise and under-deliver with penny stock promoters and penny type auditors to becoming a "real" company with respected auditors and proper marketing communications = opportunity?
The key element that separates JBI from the many other start-ups that rocket and fizzle, is that they claim to already have enough funds raised to finish the "proof of concept" and provide verifiable data on the actual efficiencies before they need to raise additional capital for the "land rush". If all this is true then the short-term stock price will not have any affect on finishing the P2O "proof of concept" which is a very unusual situation for a start-up.
If they can deliver the most efficient, cost effective and smallest foot print P2O machine available, then the stock will respond.
If I had to guess, I would guess that the possibility of de-listing is the main concern as funds would be forced to sell. I really thought that with the good news the funds would drive the price over a dollar to protect their own. If they do an RS to get the price high enough to stay listed, then that has other negative issues. IMHO it is not safe right now but it could be a great opportunity after an RS settles in.
If the company is profitable (after the deals close) and the market fails to assign a high enough value, then the company can buyback shares with the profits to the benefit of shareholders (or they could issue a dividend) and that eventually gets the markets attention and works to correct the valuation.
Mesoblast Receives TGA Regulatory Approval to Commercially Manufacture Adult Stem Cell Products
MELBOURNE, Australia, July 21 /PRNewswire/ -- Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; ADR:MBLTY), today announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cell (MPC) products.
Under this licence, Mesoblast will now make commercially available to doctors and hospitals across Australia manufactured MPC products for a patient's own, or autologous, use in the repair and regeneration of their damaged tissues. The cells will be manufactured under an agreement between Mesoblast and the TGA-licensed contractor Cell Therapies Pty Ltd.
Mesoblast will initially target major bone repair markets, including long bone fractures after trauma, stress fractures following sporting injury, and vertebral fractures due to osteoporosis.
"Gaining a licence from the TGA, one of the world's foremost regulatory bodies, to manufacture our adult stem cell products for supply to Australian patients is a major validating step in Mesoblast's history," said Mesoblast Chief Executive Professor Silviu Itescu. "It underscores the robustness of our manufacturing process and the excellent safety profile of our products in patients.
"To our knowledge, this is the first culture-expanded adult stem cell product that has received manufacturing approval anywhere in the world," he added.
Professor Itescu said that Australian TGA approval will mean early revenue generation for Mesoblast, faster product adoption and branding, and accrual of clinical outcome data for use by the Company in subsequent local and international filings for product registrations.
In addition, it will position Australia as a global leader in the use of regulated stem cell therapies.
About Mesoblast Limited
Mesoblast Limited (ASX:MSB; ADR:MBLTY) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications Director
T: + 61 (03) 9639 6036
E: julie.meldrum@mesoblast.com
SOURCE Mesoblast
Back to top
RELATED LINKS
http://www.mesoblast.com
http://www.prnewswire.com/news-releases/mesoblast-receives-tga-regulatory-approval-to-commercially-manufacture-adult-stem-cell-products-98900939.html
MORE NEWS!!! MUST READ... eom
This may have had something to do with it.
http://www.cnanalyst.com/2010/06/top-10-utility-stocks-with-highest-upside-rz-optt-chc-dyn-aes-eni-cwco-mdu-cig-elp-jun-26-2010.html
"triple digits next week!"
That would wake up a few people LOL
Sorry for the out of context quote. Just having some fun.
Phase 3 Meeting Scheduled With US FDA Following Positive Results of Bone Marrow Regeneration Trial
http://www.prnewswire.com/news-releases/phase-3-meeting-scheduled-with-us-fda-following-positive-results-of-bone-marrow-regeneration-trial-98213809.html
MELBOURNE, Australia, July 11 /PRNewswire/ -- Australian regenerative medicine company, Mesoblast Limited (ASX: MSB; ADR: MBLTY), today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration (FDA) to discuss a proposed Phase 3 clinical trial program.
For this Phase 3 program, the patented allogeneic, or "off-the-shelf," Mesenchymal Precursor Cells (MPCs) will be used under a United States FDA Orphan Drug Designation to expand haematopoietic stem and progenitor cell numbers in patients with haematologic malignancies.
Mesoblast's objective is to develop a therapy that results in effective bone marrow reconstitution without the potentially life-threatening complication of graft-versus-host disease which occurs in as many as 60 percent of patients who receive bone marrow transplants from unrelated adult donors.
In the first 25 patients transplanted with MPC-expanded haematopoietic progenitors from cord blood, 80 percent successfully achieved the key composite endpoint at 100 days of survival with sustained engraftment of both neutrophils and platelets. This is significantly higher than the rate of 38 percent for this composite endpoint achieved after transplantation with non-expanded cord blood in the United States registry of 300 patients collected by the Center for International Blood and Marrow Transplant Research. To date, only four patients (16 percent) receiving expanded cord blood have developed severe graft-versus-host disease.
"By increasing the overall success rate of an allogeneic bone marrow transplant while reducing the risk of graft-versus-host disease, our platform technology has the potential to lower the risk of infections, bleeding, and death in critically ill patients with haematologic malignancies following chemotherapy," said Mesoblast Chief Executive Professor Silviu Itescu.
"Our upcoming discussions with the FDA, based on the positive results from this trial, will enable us to provide a clear timetable to product commercialisation and early revenues," added Professor Itescu.
About Orphan Drug Designation
Orphan drug designation is reserved for therapies which are being developed for conditions affecting up to 200,000 patients annually in the United States, and allows for an accelerated review process by the FDA, seven-year market exclusivity in the United States upon obtaining marketing authorisation, tax benefits, and exemption from user fees.
About Mesoblast Limited
Mesoblast Limited (ASX: MSB; ADR: MBLTY) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications Director
+61-3-9639-6036
julie.meldrum@mesoblast.com
www.mesoblast.com
SOURCE Mesoblast Limited
Back to top
RELATED LINKS
http://www.mesoblast.com
JBI did not make any attempt to hide the fact that they paid the $1 million dollars (in stock) for the media credits. It was there in filings for everyone to see so why would anyone claim it to be fraud? The media credits will not buy any more or any less media exposure than they did before the restatement and I don't know of anyone who bought JBI stock based on the media credit valuation.
Pharma Continues Headlong Rush Into Branded Generics
By Marie Daghlian
Pharmaceutical companies’ branded generics momentum got a strong thrust with three separate emerging market deals during the second week of May. The constant reminder that emerging market pharmaceutical growth is far outpacing growth in established markets, Abbott Laboratories (ABT), GlaxoSmithKline (GSK), and Pfizer (PFE) forged new deals to solidify their global market presence.
Abbott Laboratories announced a licensing and supply agreement with Zydus Cadila, India’s fourth largest generic pharmaceutical company, for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets. Under their agreement, Abbott will gain rights to at least 24 Zydus products in 15 key emerging markets where Abbott has a strong and growing presence. The agreement also includes an option for the addition of more than 40 Zydus products to the collaboration. The deal includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in early 2012. Financial terms of the agreement were not disclosed.
At the same time, Abbott announced the formal creation of a stand-alone Established Products Division to focus on expanding the market for Abbott's established pharmaceutical portfolio in emerging markets. The new division, with $5 billion in sales, is modeled very much like Pfizer’s Established Products unit, which reported $10 billion in sales last year and has an agreement with Indian generic pharma Aurobindo for access to 60 branded generics.
GlaxoSmithKline extended its presence in Asia through a strategic alliance with South Korea's Dong-A Pharmaceuticals, acquiring a 9.9 percent stake in the company for $109.5 million. Dong-A is south Korea’s leading pharmaceutical and over-the-counter drug company. GSK has a broad agreement signed in June 2009 with India’s Dr. Reddy’s Laboratories (RDY) for access to 100 branded generics.
Not to be outdone, Pfizer expanded its partnership with Indian pharmaceutical Strides Arcolab to extend beyond the United States. Under their original agreement in January 2010, Strides was to deliver 40 products, mostly oncology injectables, for the U.S. market. The new deal will allow Pfizer to commercialize Strides’ products in the European Union, Canada, Australia, New Zealand, Japan and Korea. It also adds five new injectables to the agreement. The market size for these 45 products in the United States and covered markets is about $18 billion, according to a Reuters report. Financial terms were not disclosed.
Fresh on the heels of the U.S. Food and Drug Administration’s approval of Provenge, Dendreon’s (DNDN) cancer vaccine treatment for prostate cancer, German biotech CureVac closed a $35.25 million round with its major shareholder, dievini Hopp Bio Tech. The mRNA vaccine company is developing a prostate cancer vaccine that is currently in a phase 2a trial, with results expected in the second half of 2010. CurVac is a spin-off from Tubingen University and has raised $83 million to date. The company also has an mRNA vaccine compound to treat non-small cell lung cancer in early stage development.
San Diego diagnostics company Astute Medical completed a $26.5 million series B financing co-led by Domain Associates and Delphi Ventures. Johnson & Johnson Development and existing investor De Novo Ventures also participated in the financing.
Astute will use the funding to advance research and development aimed at the identification and validation of protein biomarkers with the goal of commercializing high potential diagnostic products. Astute’s current areas of focus include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.
Finally, Ikaria, a Clinton, New Jersey-based biopharmaceutical company filed a registration statement with the U.S. Securities and Exchange Commission to raise $200 million in an IPO. The company plans to trade on the Nasdaq under the symbol IKAR and Goldman Sachs and Morgan are serving as co-lead underwriters. Unlike many in the current IPO queue, Ikaria generated $275 million in revenue in 2009 and recorded a $13 million profit. Most of the revenue comes from Inomax, a nitric oxide drug and the only FDA-approved therapy for hypoxic respiratory failure in infants.
Financings Announced the Week Ending May 14, 2010
Global Venture Financings
Company Location Amount Raised ($M) Principal Focus
CureVac Tuebingen, Germany $36.50 Cancer Therapeutics
Astute Medical San Diego, CA $26.50 Diagnostics
BioProtein Technologies Jouy-en-Josas, France $0.66 Proteins from transgenics
iRhythm Technologies San Francisco, CA $10.00 Heart monitor
CardioDx Palo Alto, CA $5.00 Cardiovascular Diagnostics
Exosome Diagnostics New York, NY $20.00 Cancer Diagnostics
Sequent Medical Aliso Viejo, CA $15.60 Medical Devices
Coronado Biosciences Seattle, WA $7.00 Cancer Therapeutics
N30 Pharma Boulder, CO $10.00 Unmet needs
Exercise.com Mountain View, CA $1.74 Digital Health
Gynesonics Redwood City, CA $15.10 Medical Devices
AgeneBio Indianapolis, IN $0.30 CNS Therapeutics
caprotec bioanalytics Berlin, Germany $5.10 Analytic platform
ConjuGon Madison, WI $1.90 Genitourinary Therapeutics
TOTAL RAISED US $113.14
TOTAL RAISED EX-US $42.26
Grants and Contracts
Company Funding/Contracting Agency Amount ($M) Principal Focus
Enerkem (Canada) Alberta Energy $3.35 Biofuels
RegeneRx Biopharmaceuticals National Institutes of Health $3.00 Cardiovascular
PRA International Kansas BioScience Authority $0.35 Pharmaceuticals
Deciphera Pharmaceuticals Kansas BioScience Authority $0.39 Cancer
Cargill Meat Solutions Kansas BioScience Authority $0.75 Food safety
MitoSciences National Institutes of Health $0.59 Antivirals
Caliper Life Sciences Environmental Protection Agency $2.90 Toxin Screening
Total Grants and Contracts $11.33
PUBLIC FINANCINGS
Company Ticker Amount
Raised $M Financing Type
Protek (Russia) RTS:PRTK $400.00 IPO
Plethora Solutions (UK) LSE:PLE $0.45 PIPE
Mesoblast (Australia) ASX:MSB $33.30 PIPE
Micro Indentification Technologies OTC:MMTC $5.00 PIPE
Sequenom (SQNM) $51.60 PIPE
Pro-Pharmaceuticals OTC:PRWP $0.57 PIPE
NanoViricides NNVC.Pk $5.00 PIPE
Alexza Pharmaceuticals (ALXA) $1.01 PIPE
Avanir Pharmaceuticals (AVNR) $27.50 Follow-on
Pharmasset (VRUS) $87.90 Follow-on
Plethora Solutions (UK) LSE:PLE $0.39 Debt
Omnicare (OCR) $400.00 Debt
CytoSorbents OTC:CTSO $6.00 SEDA
MediciNova (MNOV) $15.00 Senior secured term loan
Pacira Pharmaceuticals Private $11.25 Credit facility
BioTime (BTIM) $8.00 Warrant exercise
TOTAL PUBLIC FINANCINGS-US $618.83
Ex-US $434.14
M&A
Acquirer Target Deal Value
in $M Focus
Ferring Pharmaceuticals (Switzerland) Xanodyne Pharmaceuticals N/A Genitourinary
Arseus (Belgium) Gallipot $12.50 Supply/service
Mesoblast (Australia) Angioblast Systems N/A Regenerative medicine
Merit Medical Systems BioSphere Medical $96.00 Medical devices
Alliances
Company/Licensee Company/Licenser Deal Value
in $M Focus
Novozymes (Denmark) Royal Nedalco (Denmark) n/a Industrial/Ag Partnership
Bristol-Myers Squibb Tekmira Pharmaceuticals (Canada) $3.00 RNAi Therapeutics Collaboration
Genentech (Roche-Switzerland) Evotec (Germany) N/A Drug Discovery Alliance
Abbott Laboratories Zydus Cadila (India) N/A Emerging Markets License
GlaxoSmithKline Dong-A Pharmaceuticals (South Korea) $109.50 Emerging Markets Alliance
Roche (Switzerland) Galapagos (Belgium) $188.73 Respiratory Alliance
Boehringer Ingelheim (Germany) Intercell (Austria) N/A Animal Vaccines Partnership
GlaxoSmithKline (United Kingdom) Response Genetics N/A Molecular Diagnostics License
Pfizer Ergonex Pharma (Germany) N/A Vascular Therapeutic License
St Jude Medical iRhythm Technologies N/A Consumer Digital Health Partnership
GE Healthcare CardioDx N/A Diagnostic License
GE Healthcare West Wireless Health Institute N/A Digital Health Collaboration
Pfizer Strides Arcolab (India) N/A Oncology Generics License Expansion
SeekingAlpha - Henry W McCusker's Instablog
http://seekingalpha.com/instablog/438392-henry-w-mccusker/68416-angioblast-acquired-by-mesoblast-asx-msb-adr-mblty
Mesoblast is acquiring the outstanding shares of Angioblast Systems, a developer of mesenchymal precursor cells to position its marketing operation in 2012. The acquisition valued Angioblast at $222 M and gives Mesoblast a value of $405 M. Referencing our previous post, 5/10/10.
MSB swapped its shares for the 67% of Angioblast it doesn’t already own. The Angioblast package comes with the IP to experimental therapies for diabetes, cardiovascular disease and eye disease, as well as a leukemia program. The acquisition enables MSB to focus on 3 simultaneous commercial strategies: taking lead products to market on our own and retaining 100% of the commercial upside, entering into distribution agreements to leverage sales/marketing strength, and partnering through broad-based strategic alliances.
MSB, also announced it has completed a capital raising of $37 M to fund the acquisition and advance operations. These funds comprise $24 M invested immediately and $13 M committed subject to both shareholder approval and completion of the acquisition offer.
Angioblast’s lead program relies on mesenchymal precursor cells to articulate umbilical cord blood used in the bone marrow transplants needed by leukemia patients. But, will a late-stage trial this year confirm the results of a small study involving 18 patients to effectively restore the white blood cells the body relies on to fight infections? Another therapy, Revascor, is designed to restore cardiovascular muscles in heart attack victims. Mesoblast estimated that Angioblast’s therapies could generate up to $500 M upon regulatory approval. (HWM and Bloomberg)
Don't forget the "Media" event that was touted by "Honest John". My guess would be that the last bull on this this board must be sacrificed before we get our turnaround ;(
The real problem I see is the damage to JBI in investors eyes which will probably make it a "trading" stock and no longer a "buy and hold" stock which would make it harder to sustain a price that would allow for rapid expansion (assuming that JBI proves istself as a viable company).
Raser Technologies Announces Extension of Thermo No. 1 Final Completion Date
Date : 07/01/2010 @ 8:00AM
Source : Business Wire
Stock : Raser Technologies, Inc. (RZ)
Quote : 0.58 -0.005 (-0.85%) @ 8:00PM
Today : Thursday 1 July 2010
Raser Technologies, Inc. (NYSE: RZ), an energy technology company, announced today that it reached an agreement to extend the Final Completion Date for the Thermo No. 1 project from June 30, 2010 to July 9, 2010, after which time Raser expects to provide an update on the project, including final payment arrangements to the financing parties from the U.S. Treasury grant proceeds received earlier this year.
“This extension will give us time to work with our project financing partners in evaluating the performance of the plant and final distribution of the funds from the Treasury grant still in escrow,” commented Raser’s Executive Vice President Dick Clayton.
Construction on the Thermo No. 1 project began in July 2008 and the plant began selling electricity to Anaheim, CA in April 2009. In February 2010, Thermo No. 1 received $33 million dollars from the U.S. Treasury Department under the Section 1603 renewable energy grant program created by the American Recovery and Reinvestment Act of 2009.
About Raser Technologies
Raser (NYSE: RZ) is an environmental energy technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment develops clean, renewable geothermal electric power plants with one operating plant in southern Utah and eight active and early stage projects in four western United States: Utah, New Mexico, Nevada and Oregon, as well as a concession for 100,000 acres in Indonesia. Raser’s Transportation and Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
Jesup & Lamont Fires Staff After FINRA Order
http://pipes.dealflowmedia.com/wires/article.cfm?title=Jesup-Lamont-Fires-Staff-FINRA-Order&id=wuwuraxrirfhaeh
Posted June 30, 2010 11:21AM PST
PIPE placement agent Jesup & Lamont said it's terminating all non-essential personnel after the Financial Industry Regulatory Authority ordered the firm to stop doing business last week.
The firings announced yesterday followed a June 21 order by FINRA that called for Jesup & Lamont Securities Corp. to stop conducting a securities business, other than liquidating transactions, because of its failure to meet net capital rules.
Based in Longwood, Fla., Jesup & Lamont had facilitated at least 49 PIPEs that raised $319.7 million from 2001 through May of this year.
Do you know if the recent PIPE was only offered to those who were also part of the $.80 original PIPE (not to imply that everyone in the original pipe was offered the recent PIPE but basically asking if the recent PIPE had any "new" investors)?
Thanks,
Hey that was funny.
Have they put the "odor" into the natural gas yet (cause that would not be funny)?
Yea that caught my attention also in 2007 as you can see here...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=18416022
So they have had several years since and have not impressed investors with the stock falling from $.40-$.50 to the current $.03. I still follow the story but just watching with a jaded eye for now. They would need to get a large government contract to get investors attention. At least the board is easy to follow - lol
Do you know anything about these two United States Defense Contracts in 2009 for $95,350?
http://www.governmentcontractswon.com/department/defense/contractors359.asp
This is a unique situation in pennyland. IF JB is correct in his last assessment that JBIIE has the cash to complete the current P2O project to full operation & finish the Pak-it roll out, THEN the stock price fluctuations should not impair JBIIE progress as their is no need to sell shares to fund the current short term projects. WHEN those projects are completed and we all get to see exactly what income is generated, THEN there will be a basis on which to fund rapid expansion and the stock price will move accordingly.
However, the clock is ticking for shareholders as I do have concerns that come July 1st, restricted shares will hit the market and that "factor" is already weighing on the JBIIE stock price and will continue to do so until the impact of this "unknown" is known.
I did not make the AGM so please tell me you are joking because that is the dumbest idea I have heard of from JBI. The Pak-it concept advantage is to save shipping costs by shipping concentrated soaps without the water and reuse the plastic spray bottles which is ecologically responsible and also cost savings. Pak-it is also being used to produce the catalyst, so I get that. However, have you ever bought bubble bath that was already diluted? Any bubble bath you buy is already concentrated so the major advantage is lost except for a possible convenience factor. IMHO
If they only changed their name to "CHINA ORGANIC STEVIA PRODUCERS" investors would find them and the price would triple. LOL
Mesoblast Limited (ASX:MSB) Featured At ASX Singapore Conference Highlighting Emerging Market Leaders
Melbourne, May 28, 2010 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.
Mesoblast was one of only two emerging market leaders in the healthcare sector that were showcased to around 150 targeted global investors. The conference featured only 15 companies, predominantly from the resources sector, with market capitalisations of up to A$1 billion.
Chief Executive, Professor Silviu Itescu, updated investors on Mesoblast's acquisition of its United States associate company, Angioblast Systems, its near term growth strategies and plans for early product revenues.
Background
Mesoblast Limited is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).
Link: http://www.abnnewswire.net/media/en/docs/62968-ASX-MSB-336948.pdf
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
Tel: +61-3-9639-6036
Mob: +61-419-228-128
Email: julie.meldrum@mesoblast.com
www.mesoblast.com
E_P thanks. This is a must read post as creates an accurate assessment of the current situation and the opportunity it provides.
http://www.worldmarketmedia.com/779/section.aspx/1624/post/todays-small-cap-market-mover-otcbbjbii
Are these media credits at work?
We seem to be going up on a down day and right before we get the (E)? Interesting.
Credibility is lost here and will need to be rebuilt. In the corporate business world nothing has been done until the paperwork is correctly done. Media credits should have been properly addressed months ago when questioned but now they are part of a costly setback to the NASDAQ uplisting.
Can we now stop all the rhetoric (game-over, blow the __ up, 100% right since $.20, HonestJohn) and address the "good, bad and ugly" as a stock not a cult? I still think that P2O is the real deal and will prove itself over time but it looks like the "ugly" may not be over unless things actually start happening before the PIPE shares become unrestricted. I'm just glad this is not the only stock I own. John needs some good advisers to teach him the ropes of being a CEO of a publicly traded company. I'm glad he has thick skin and should appreciate this little humor relief cartoon.
United States FDA Clears Mesoblast Limited (ASX:MSB) Phase 2 Trial For Cervical Spinal Fusion
http://www.abnnewswire.net/press/en/62897/
Thank you for the honesty that you provide. When I'm soaking wet and cold in the rain, I don't need someone to tell me to "be happy, the sun will come out tomorrow". However, I still have belief that JB will do what he set out to do long-term with P2O but it would have been nice if expectations on this board has not been set so high on the timing (as I have tried to warn). Still, a lot of people who have watched this stock and thought they missed out on lower prices could be interested now and traders bring volume and tighten spreads which is good for everyone. Even though I held, I congratulate all those who sold higher and are able to increase their shareholdings. I know JB is at the mercy of permit red tape and the NASDAQ but I agree that filings need to be a higher priority for JBII if they want investors to support the stock. I hope I am wrong but I just don't see NASQAQ approving a company that is not current with financials and is under $4 (I know $4 is not an uplisting issue directly but when was the last time you saw an OTCBB stock go to the NASDAQ to be under $4). These issues could be resolved quickly and I hope that they are. As long as the P2O promised efficiencies are proven true long term should be excellent for all current stock holders no matter what price. Market timing is not my thing and I have lots of other projects I should be doing besides reading these boards so I'm going to try and minimize my time here. Peace.
Bloomberg article on Mesoblast in Business Week...
http://www.businessweek.com/news/2010-05-12/stem-cell-developer-mesoblast-seeks-bone-marrow-therapy-by-2012.html
Bloomberg
Stem Cell Developer Mesoblast Seeks Bone Marrow Therapy by 2012
May 12, 2010, 5:39 AM EDT
By Simeon Bennett
May 12 (Bloomberg) -- Mesoblast Ltd., an Australian developer of stem-cell therapies, aims to introduce its first product by 2012 after agreeing to buy the shares of Angioblast Systems Inc. it doesn’t already own.
Mesoblast will issue new shares to the unidentified owners of closely held Angioblast to acquire the remaining 67 percent of the company, Melbourne-based Mesoblast said in a statement today. Mesoblast also raised A$37 million ($33 million) selling shares to investors. The company will use the money to fund patient studies, Chief Executive Officer Silviu Itescu said.
The purchase, which values New York-based Angioblast at about A$250 million, gives Mesoblast full rights to treatments for heart failure, eye disease, diabetes and a stem cell treatment for leukemia patients requiring a bone marrow transplant. The market for such patients may be between $300 million and $500 million a year, Itescu said.
“Apart from the breadth of products that it gives Mesoblast, it gives us more mature programs that are moving their way through to conclusions and revenues,” Itescu said in a telephone interview today.
The shares rose 2.8 percent to A$1.99, reversing a 3.9 percent decline in earlier trading. They have more than doubled during the past 12 months, compared with an 18 percent advance in the All Ordinaries Index.
Cord Blood
Angioblast’s bone marrow treatment uses a type of stem cell called mesenchymal precursor cells to expand umbilical cord blood used in marrow transplants, while reducing the risk of the donor’s marrow attacking the patient, a potentially fatal complication.
In a trial of the technology in 18 patients last year, the stem cells expanded cord blood 40-fold. When transplanted, the marrow restored the number of infection-fighting white blood cells to normal levels in a median of 16 days and platelets in 38 days, compared with 30 days and 90 days in previously published reports of patients treated with unexpanded cord blood.
Mesoblast plans to study the treatment in the third and final stage of patient trials normally needed for U.S. regulatory approval later this year and is aiming to get approval in 2012, Itescu said.
Mesoblast also gains full rights over Angioblast’s Revascor, a stem-cell treatment designed to repair cardiovascular muscles in patients who have had a heart attack. In a trial of the treatment among 40 heart attack survivors last year, patients had an average 22 percent increase in the amount of blood their hearts pumped with each beat, compared with an 18 percent decrease among those who took a placebo.
‘Potential Game Plans’
The combined company, to be called Mesoblast Group, will have a market value of about A$455 million, excluding the sale of additional shares, Mesoblast said.
The company plans to sell some products, such as its bone marrow treatment, by itself and to license others to partners, Itescu said. Selling Mesoblast to a larger company is “one of the potential game plans,” he said.
“To maximize our commercial opportunities, we need to be able to rationally review the product suite so we can allocate resources to those products which make the most sense in terms of profitability,” he said. “We’re in a number of discussions with a variety of partners across several of our lead applications.”
Mesoblast, which reported cash reserves of A$12.6 million as of March 31, sold new shares to investors from the U.K. and Australia at A$1.70 apiece, 12 percent less than the company’s closing share price on May 3.
--Editors: Carey Sargent, Jason Gale
To contact the reporter on this story: Simeon Bennett in Singapore at sbennett9@bloomberg.net
To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net.
I would like to clarify a previous post as I am getting PM's from a couple who may have misunderstood my post...
Hopefully they learned their lesson on penny stock promotions. Interesting technology but I passed on this because of the promotion and now I'm just watching, lurking.
When are the results of the CO2 competition supposed to be released?
It seems like a lot of companies are trying to "capture" this market...
http://www.zdnet.com/blog/green/dont-just-put-a-lid-on-it-companies-test-co2-conversion-tech/11619%29
Expanding production 10x - Did I miss a different year in ITRO history when that happened? I would say that is different and couple that to the highest ever sales before the expansion and it just becomes a matter of time. Again, it took many years to get to this point and the market will not believe anything except sales because it has "cried wolf" for so long so stock promotion would be a waste of money and counterproductive. The final 100x (of current production) will be the icing on the cake for shareholders who have been put through the ringer on this stock. IMHO
Exactly. It is in place to protect the company because it is still a very small company. This also makes it good for the long-term shareholders who want to see the P2O growth without concern of another company buying them out before the value is maximized. I was not able to attend the AGM but I hear that over 400 shareholders attended and I understand that they were very pleased with JBI's business progress. I know the stock price may have some great fluctuations until the investment community is convinced that P2O is the real deal but I like the risk/reward ratio on JBII.
JB was the majority shareholder before he returned his shares. He had control before he exchanged his shares for 100-1 preferred which does not have a conversion to common. He basically gave his personal shares to fund JBII growth. I don't see how this can be construed as a negative. Could he change everything? Yes, because he is in control. If you do not trust JB's control, then maybe you should invest elsewhere because I do not see that changing and every other aspect of discussion (earnings, acquisitions, growth, marketcap... ) would be moot.
Good questions. I will be looking for the answers just like you. I suspect it that it either has to do with the NASQAQ application or JBI decided that the shareholders would benefit from a firm with more clout, but either way I see it as a long-term positive although the uncertainty could have a negative impact on the stock until more is known.
Nice red letter edition. Thanks for giving a thoughtful, courteous and reasonable reply. Everyone knows that the market is forward looking so when we get permits and upon validation of JBI selling oil/diesel/NG, the market will respond quickly. It is only the timing that is speculation to me at this point. The stock could go on very wild swings up and down in the next 6 months but I am not generally an active trader. I don't sit and watch the market all day so taking the chance of being on the sidelines when several market moving events could happen at any time, does not work for me.
I believe the most critical skeptics on this stock are traders not buy and hold investors. You can bet they have JBII on their trade screen ready to jump in for a quick trade but they have no long-term interest in JBI. This is why they cannot even remember the "dd" that they themselves posted a month earlier.